Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,961 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,853 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05741242 | A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 136 | Jaime Leandro Foundation for Therapeutic Cancer VaccinesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06936527 | XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation(XS-03-II201) | enrolling by invitation | Phase 1 / Phase 2 | 102 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
| 1 |
| Sep 25, 2026 |
| clinicaltrials |
| NCT07344220 | Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate(DZ-002-201) | enrolling by invitation | Phase 2 | 39 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03628612 | Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells | enrolling by invitation | Phase 2 | 500 | Autolus LimitedINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06987058 | RVU120 Rollover Study(ROVER-01) | enrolling by invitation | Phase 2 | 14 | Ryvu Therapeutics SAINDUSTRY | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07822347 | Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors | enrolling by invitation | Phase 1 / Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07775209 | Shortening Radiation Course Duration Using Simultaneous Integrated Boost With Lower Intensity Elective Nodal Dosing and Concurrent Chemotherapy for High-Risk Anal Squamous Cell Carcinoma(SSIBLING) | enrolling by invitation | Phase 2 | 24 | University of Vermont Medical CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07813390 | Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure(HLA-AML) | enrolling by invitation | Phase 2 | 73 | Guangdong Second Provincial General HospitalOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06910072 | Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)(UPGRADE-TNBC) | enrolling by invitation | Phase 2 / Phase 3 | 32 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06680596 | Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy(SAFIR3LibHERty) | enrolling by invitation | Phase 2 | 80 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05669989 | International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | enrolling by invitation | Phase 2 | 70 | SanofiINDUSTRY | 17 | Jul 31, 2026 | clinicaltrials |
| NCT07738367 | Bronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLC | enrolling by invitation | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04093570 | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | enrolling by invitation | Phase 2 | 332 | Taiho Oncology, Inc.INDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | enrolling by invitation | Phase 2 | 48 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT07690761 | Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant(Rituximab+ Zan) | enrolling by invitation | Phase 2 | 12 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07683949 | Clinical Trial Evaluating the Efficacy of Capecitabine Plus Lenvatinib in Patients With Advanced Colorectal Cancer Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidine(LENCAP-CRC) | enrolling by invitation | Phase 1 / Phase 2 | 93 | Seoul National University Bundang HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07139951 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | enrolling by invitation | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07275463 | [99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression | enrolling by invitation | Phase 2 | 40 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07292571 | Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107 | enrolling by invitation | Phase 2 | 50 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03393962 | Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors | enrolling by invitation | Phase 1 / Phase 2 | 20 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07651163 | Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 450 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651176 | Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 267 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07618624 | BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression(BRIDGE) | enrolling by invitation | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT00900497 | A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers | enrolling by invitation | Phase 1 / Phase 2 | 29 | Dipnarine MaharajOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07550582 | Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction(SAVE-GEJ) | enrolling by invitation | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07542262 | Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers(NIVO402025) | enrolling by invitation | Phase 2 | 128 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07550972 | Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. | enrolling by invitation | Phase 2 | 30 | Zhejiang Provincial People's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07542158 | Ultralow Dose PET Imaging of 18F-FDOPA | enrolling by invitation | Phase 2 | 200 | Akiva MintzOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07537257 | VEN+IDAC vs IDAC in AML | enrolling by invitation | Phase 2 / Phase 3 | 232 | Guangdong Second Provincial General HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07517510 | HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).(HVA-MPAL) | enrolling by invitation | Phase 2 | 40 | Guangdong Second Provincial General HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06763965 | Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | enrolling by invitation | Phase 1 / Phase 2 | 30 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07126990 | Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma | enrolling by invitation | Phase 1 / Phase 2 | 40 | Xiaorong WuINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | enrolling by invitation | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06650748 | Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer(NeoMARS) | enrolling by invitation | Phase 2 | 100 | Peking UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05441475 | A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | enrolling by invitation | Phase 2 | 118 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06250777 | Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases(ELPIS) | enrolling by invitation | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07376629 | A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC | enrolling by invitation | Phase 2 | 60 | Huabo Biopharm Co., Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06370416 | the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib | enrolling by invitation | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07363031 | Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy | enrolling by invitation | Phase 2 | 84 | Instituto OncoclinicasOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07359404 | Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC | enrolling by invitation | Phase 2 | 60 | YING FANOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma | enrolling by invitation | Phase 2 | 48 | Peking UniversityOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07310069 | Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer(TRANSFORM-GBC) | enrolling by invitation | Phase 2 | 44 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06843681 | Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study | enrolling by invitation | Phase 2 | 54 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT06544798 | Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia | enrolling by invitation | Phase 2 | 276 | MeiraGTx, LLCINDUSTRY | 2 | Oct 16, 2025 | clinicaltrials |
| NCT07121478 | Patients With High-grade Pancreatic Neuroendocrine Tumors | enrolling by invitation | Phase 2 | 46 | National Cancer Center, KoreaOTHER_GOV | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05893654 | Melphalan Chemoreduction for Ocular Melanoma(MELCOM) | enrolling by invitation | Phase 1 / Phase 2 | 10 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07130149 | Sonodynamic-Chemoradiotherapy Integration in Glioblastoma | enrolling by invitation | Phase 2 | 230 | Yingjuan ZhengOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05385861 | Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET | enrolling by invitation | Phase 1 / Phase 2 | 52 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07101900 | 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | enrolling by invitation | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 1 | Aug 8, 2025 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 29, 2026source: clinicaltrials